Share on Facebook
Share on Twitter
Share on LinkedIn
Share by Email
Print
23andMe announced an agreement with Pfizer for a research initiative designed to study the genetic factors associated with the onset, progression, severity, and response to treatment for inflammatory bowel disease (IBD).
The companies plan to enroll 10,000 patients with IBD who will receive 23andMe’s Personal Genome Service, including their ancestry analysis and uninterpreted raw genetic data. The study’s eligibility criteria include current non-23andMe customers that have been diagnosed with Crohn’s disease or ulcerative colitis by a qualified physician. Recruited patients will need to consent to provide a DNA sample (saliva), participate in online surveys, and share their data with researchers.
RELATED: New Assay to Diagnose, Differentiate IBD and IBS
Researchers hope to apply the findings of this study to Pfizer’s drug development to discover better treatment options for patients with IBD.
For more information visit 23andMe.com.
